Sloan-kettering Institute for Cancer Research

Memorial Sloan Kettering Cancer Center

Adjuvance Technologies, Inc.

Govind Ragupathi

Philip O Livingston

David Y Gin

David Gin

Kai Deng

Samuel J Danishefsky

Jason S Lewis

Derek Shieh Tan

Jeffrey R Gardner

Eric K Chea

Lars Nordstroem

Michelle Adams

Naga Vara Kishore Pillarsetty

J Tyler Martin

Nicholas Perl

Annie Won

Jianglong Zhu

Nai-Kong V Cheung

Alberto Fernandez-Tejada

David Spriggs

Shakeel Modak

Dongjoo Lee

Alberto Fernandez-tejada

Naga Vara Pillarsetty

The present disclosure provides methods for enhancing the immunogenicity of a poorly immunogenic antigen-specific vaccine as well as methods for promoting diversification of the gut microbiome in a subject in need thereof comprising administering to the subject an effective amount of a beta-glucan extract derived from yeast. Kits for use in practicing the methods are also provided.

Methods of enhancing immunogenicity of poorly immunogenic antigen-specific vaccines using oral yeast beta-glucans

The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.

Triterpene saponin analogues

Glycopeptide conjugates, and methods of making and using such conjugates are disclosed. Certain glycopeptide conjugates comprise tumor associated carbohydrate antigens and peptide epitopes. Certain glycopeptide conjugates comprise cyclic peptide scaffolds that display carbohydrate antigens in a clustered fashion. The immunogenicity of select glycopeptide conjugates is demonstrated.

Glycopeptide constructs and uses thereof

Glycopeptide conjugates comprising GM2 and/or Gb5 carbohydrate determinants, and methods of making and using such conjugates are disclosed. The immunogenicity of select glycopeptide conjugates is demonstrated.

Multivalent glycopeptide constructs and uses thereof

The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.

Triterpene saponins, methods of synthesis, and uses thereof

Growing community of inventors

New York, NY, United States of America

Govind Ragupathi